Minimal change disease (MCD) is a kidney condition where the filtering units of the kidneys leak large amounts of protein into the urine, leading to a cluster of symptoms called nephrotic syndrome. It gets its name from a quirk of diagnosis: kidney tissue looks completely normal under a standard microscope, and the damage only becomes visible with powerful electron microscopy. MCD is the most common cause of nephrotic syndrome in children and accounts for 10 to 15% of cases in adults.
Why Protein Leaks Into the Urine
Your kidneys filter blood through tiny structures called glomeruli. Each glomerulus has a multi-layered barrier that keeps useful proteins, especially albumin, in your bloodstream while letting waste pass through into urine. One critical layer is made up of specialized cells called podocytes, which wrap around blood vessels and interlock like fingers to form a tight seal.
In MCD, those finger-like extensions (called foot processes) flatten out and lose their interlocking structure. This is known as foot process effacement, and it’s the hallmark finding on electron microscopy. With the seal broken, albumin and other proteins slip through into the urine. The leading theory is that a circulating substance produced by immune cells triggers this damage. Recent research has also identified autoantibodies that target a key protein in the podocyte seal in some patients, suggesting an autoimmune component in at least a subset of cases.
There’s growing evidence that the damage may not start with podocytes alone. The innermost lining of the kidney’s blood vessels has its own protective coating, a negatively charged mesh called the glycocalyx. When this coating is degraded, it may allow proteins to reach and injure the podocytes underneath. This means MCD could involve damage to multiple layers of the kidney’s filtration barrier, not just one.
Symptoms and How It Feels
The hallmark of MCD is nephrotic syndrome, which produces a recognizable set of symptoms. The most noticeable is swelling, particularly around the eyes in the morning and in the ankles and legs later in the day. This happens because losing albumin from the blood reduces its ability to hold onto fluid, so water seeps into surrounding tissues. The swelling can be dramatic, sometimes causing a person’s weight to increase by several pounds in just days.
Other features include foamy or frothy urine (from the high protein content), fatigue, and sometimes loss of appetite. Blood tests typically show low albumin levels, often below 2.5 g/dL, and elevated cholesterol. The body ramps up cholesterol production in the liver as a response to falling protein levels, which is why high cholesterol is a consistent part of the picture. There is also an increased risk of blood clots, since some of the proteins lost in the urine help regulate clotting.
Who Gets It
MCD is primarily a disease of childhood. It accounts for the vast majority of nephrotic syndrome cases in young children, with a typical onset between ages 2 and 6. In adults, it’s less common but still significant, ranking as the third most frequent cause of primary nephrotic syndrome. Adult-onset MCD tends to be more complicated, with a higher risk of acute kidney injury and a longer path to remission.
Diagnosis in Children vs. Adults
In children presenting with classic nephrotic syndrome, the diagnosis of MCD is often presumed without a kidney biopsy. Because it’s so overwhelmingly the most likely cause in that age group, doctors typically start treatment and see if the child responds. A good response to steroids essentially confirms the diagnosis.
Adults follow a different path. Because nephrotic syndrome in adults has a wider range of possible causes, a kidney biopsy is generally needed to make a definitive diagnosis. During the biopsy, a small sample of kidney tissue is examined. Under a standard light microscope, the tissue looks normal, which is where the “minimal change” name comes from. The characteristic foot process effacement only appears under electron microscopy. Urine testing confirms nephrotic-range protein loss, defined as more than 3 to 3.5 grams of protein in a 24-hour collection for adults.
First-Line Treatment With Steroids
MCD responds well to corticosteroids, which is one of its defining features. The standard approach for adults is oral prednisone at a dose of about 1 mg per kilogram of body weight per day, up to a maximum of 80 mg daily. This is maintained for at least 4 weeks, sometimes extending up to 16 weeks depending on response.
The timeline to remission varies. Some patients see protein levels drop within 2 weeks, while others take longer. Across large case series, the median time to remission has ranged from about 5 to 13 weeks. By 8 weeks, roughly two-thirds of adults achieve complete remission, and by 16 weeks, nearly 90% do. With treatment extended to 24 weeks, up to 90% of adults reach full remission, though at the cost of prolonged steroid exposure and its side effects. Once protein levels normalize, the steroid dose is gradually tapered over several weeks to months.
Relapses and Long-Term Course
While the initial response to steroids is usually excellent, relapses are common. More than half of adult MCD patients experience at least one relapse after their first episode. About a third become frequent relapsers or find they can’t taper off steroids without the disease coming back, a pattern called steroid dependence. Each relapse is typically treated with another course of steroids, but repeated cycles bring cumulative side effects: weight gain, bone thinning, elevated blood sugar, cataracts, high blood pressure, skin changes, and increased vulnerability to infections.
An estimated 10% of adult patients are considered steroid-resistant, meaning they fail to achieve remission even after 16 weeks of daily or alternate-day corticosteroid therapy. This group requires a different treatment strategy.
Options Beyond Steroids
For people who relapse frequently, can’t come off steroids, or don’t respond to them at all, several second-line medications can help. These are sometimes called steroid-sparing agents because they reduce or eliminate the need for long-term steroid use. The most commonly used options include calcineurin inhibitors (cyclosporine and tacrolimus), which suppress specific immune pathways involved in the disease, and mycophenolate, which broadly dampens the immune system’s activity.
Cyclophosphamide, an older immunosuppressive drug, is also used in some cases. More recently, rituximab, a medication that targets and depletes a specific type of immune cell called B cells, has shown promise in patients with difficult-to-manage MCD. The discovery of anti-nephrin autoantibodies in some patients provides a potential explanation for why B cell depletion works: if the disease is driven by antibodies attacking the kidney’s filtration barrier, removing the cells that produce those antibodies could halt the cycle.
Acute Kidney Injury in MCD
One of the more serious complications of MCD is acute kidney injury, which occurs in 20 to 25% of adult cases. This means the kidneys suddenly lose some of their filtering ability on top of the protein leakage. Risk factors include older age, male sex, high blood pressure, very heavy protein loss, and severely low albumin levels. The good news is that this kidney injury is usually reversible with steroid treatment. However, in a small number of patients, particularly older adults with multiple risk factors, the damage can become permanent.
The risk of blood clots is another concern during active disease. The loss of clotting-regulating proteins through the urine creates a state where clots form more easily, which can affect the legs or, less commonly, the lungs or kidneys.
Long-Term Outlook
MCD carries a generally favorable prognosis compared to many other kidney diseases. It rarely progresses to permanent kidney failure. The main burden of the disease is the relapsing-remitting pattern and the side effects of repeated steroid courses. For children, the outlook is especially good, with most eventually outgrowing the tendency to relapse. Adults face a more prolonged course, but with the steroid-sparing options now available, most people can achieve sustained remission and preserve their kidney function over the long term.